GPCR News 

Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...

Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update

Addex raises $4.2 million in equity financing

Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...

Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...

Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...

Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10

Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia

Addex Raises $10 Million In Equity Financing

Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has...